Australia’s R&D effort is focused around medical technologies and here in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Dig Howitt of Cochlear outlines the way ahead to support innovation in the sector. Cochlear has long been a pioneer in innovation. It has reshaped hearing technology and made substantial contributions…
Hearing implant manufacturer Cochlear has reported a 20 percent jump in sales for the half year ended December, 2023 to $1.1 billion, driven by strong growth in cochlear implants and sound processor software upgrades. Cochlear implant units increase by 14 percent as the company consolidated market share gains and strong growth in developed and emerging…
By Peter Roberts The news that contract manufacturer Neo-Bionica has established Australia’s first facility capability of hermetically sealing implantable medical devices brings to mind the story of how Cochlear’s manufacturing skills in the area kept it from going offshore – and remain a secret of its success. The process of hermitization which Neo-Bionica is now…
Hearing implant manufacturer Cochlear has revealed that sales jumped 19 per cent, or 16 percent in constant currency terms, in the year ended June to reach $1.96 billion. Sales were driven by the release of new products and as clinicians caught up with implant surgeries postponed during the Covid-19 pandemic. The company, which launched its…
Hearing implant manufacturer Cochlear can move ahead with its purchase of competitor Oticon Medical’s cochlear implant following a positive finding from the UK Competition and Markets Authority (CMA). However Cochlear will not be able to purchase the entire Oticon business as it initially hoped. CMA published its final report on the proposed acquisition, concluding that…
Hearing implant manufacturer Cochlear has again rebuffed competition concerns from authorities over its planned takeover of competitor Oticon Medical for $170 million, which followed a decision by parent company Demant to exit the hearing implants business. Cochlear said it disagreed with the conclusions of the UK Competition and Markets Authority (CMA) which found provisionally that…
Hearing implant manufacturer Cochlear has powered to a new first half record revenue based on new product offerings and as the company completes its recovery from the pandemic. The Sydney company reported sales revenue up nine percent (seven percent in in constant currency terms) to a record $893 million, revealing strong growth in cochlear and…
Hearing implant manufacturer Cochlear has rejected competition concerns raised by the Australian Competition and Consumer Commission (ACCC) over its proposed acquisition of Oticon Medical. The ACC said in a statement that the proposed takeover of non-surgical bone conductive hearing device manufacturer Oticon raised ‘preliminary competition concerns’ due to there being few global manufacturers of such…
Hearing implant manufacturer Cochlear has finally shaken off the negative effects of the Covid-19 pandemic on cochlear implant surgeries, notching up a sales revenue increase of 10 percent to reach a record $1.6 billion in FY22. During the pandemic implant surgeries stalled in all markets including China and the United States, with the company now…
Cochlear may have grown its sales from the depths of a Covid-19 slump in sales and surgeries to reach a new record level in FY 22, but the company has not returned to what it was before the pandemic. The maker of Cochlear implants reported sales revenue grew 10 per cent in the year to…
